Aranda Richard

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 24

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2029-03-25

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 23

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,167

Underlying: Common Stock · 9,167 shares

Expires 2029-12-23

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 22

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,784

Underlying: Common Stock · 22,784 shares

Expires 2030-02-14

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 21

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2031-02-25

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 20

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2031-06-21

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 19

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,667

Underlying: Common Stock · 126,667 shares

Expires 2032-01-05

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 18

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,500

Underlying: Common Stock · 157,500 shares

Expires 2032-12-06

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 17

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,500

Underlying: Common Stock · 157,500 shares

Expires 2033-03-19

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 16

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,500

Underlying: Common Stock · 162,500 shares

Expires 2033-11-19

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 15

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 487,500

Underlying: Common Stock · 487,500 shares

Expires 2034-01-01

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 14

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 572,000

Underlying: Common Stock · 572,000 shares

Expires 2035-03-03

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 13

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 562,500

Underlying: Common Stock · 562,500 shares

Expires 2036-01-01

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 12

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2029-03-25

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 11

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,167 shares

Expires 2029-12-23

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 10

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,784 shares

Expires 2030-02-14

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 9

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2031-02-25

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 8

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2031-06-21

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 7

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 126,667 shares

Expires 2032-01-05

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 6

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 157,500 shares

Expires 2032-12-06

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 5

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 157,500 shares

Expires 2033-03-19

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 4

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 162,500 shares

Expires 2033-11-19

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 3

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 487,500 shares

Expires 2034-01-01

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 2

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 572,000 shares

Expires 2035-03-03

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000004 · wk-form4_1774038115.xml · derivative · entry 1

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 562,500 shares

Expires 2036-01-01

F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0001867872-26-000002 · wk-form4_1767649091.xml · derivative · entry 3

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 562,500

Underlying: Common Stock · 562,500 shares

Expires 2036-01-01

F2 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on January 2, 2027 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001867872-26-000002 · wk-form4_1767649091.xml · nonDerivative · entry 1

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 463,106

F1 · shares: Represents restricted stock unit award, which will vest in four equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date.

SEC source: 0001867872-25-000003 · wk-form4_1759436003.xml · nonDerivative · entry 1

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 369,356

F1 · shares: Represents performance stock unit award, which will vest in full upon the earlier of (i) the approval of a new drug application for seralutinib or (ii) a change in control, in either case on or prior to the fourth anniversary of the grant date, and subject to the Reporting Person's continuous service to the Issuer.

SEC source: 0001728117-25-000012 · wk-form4_1741295144.xml · derivative · entry 1

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 572,000

Underlying: Common Stock · 572,000 shares

Expires 2035-03-03

F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on March 4, 2026 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001728117-24-000078 · wk-form4_1719354282.xml · nonDerivative · entry 1

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 196,891

F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

SEC source: 0001728117-24-000034 · wk-form4_1710888644.xml · nonDerivative · entry 1

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 198,799

F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: This transaction was executed in multiple trades at prices ranging from $1.329 to $1.331 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

SEC source: 0001728117-24-000006 · wk-form4_1704405870.xml · derivative · entry 1

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 487,500

Underlying: Common Stock · 487,500 shares

Expires 2034-01-01

F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on January 2, 2025 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001728117-23-000148 · wk-form4_1700698065.xml · derivative · entry 1

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,500

Underlying: Common Stock · 162,500 shares

Expires 2033-11-19

F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on November 20, 2024 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001728117-23-000086 · wf-form4_168780970194929.xml · nonDerivative · entry 1

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 197,574

F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: This transaction was executed in multiple trades at prices ranging from $1.285 to 1.29 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

SEC source: 0001728117-23-000057 · wf-form4_168366370450924.xml · derivative · entry 12

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,667

Underlying: Common Stock · 126,667 shares

Expires 2032-01-05

F13 · derivative.exercise_price: The exercise price of the option is $1.36 per share, representing the fair market value per share of the Issuer's common stock on the date of grant; provided that in the event the option is exercised prior to May 5, 2024, or the Reporting Person's employment terminates prior to May 5, 2024 other than due to death, disability or circumstances giving rise to severance under the Reporting Person's employment agreement, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F12 · price: On May 5, 2023, the Issuer canceled an option granted on January 6, 2022. In exchange for the canceled option, the reporting person received 126,667 options to purchase common stock having a lower exercise price with the same vesting terms.

F11 · derivative.exercise_date: One-third of the total number of shares subject to the option vested on January 6, 2023 and 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001728117-23-000057 · wf-form4_168366370450924.xml · derivative · entry 11

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2031-06-21

F13 · derivative.exercise_price: The exercise price of the option is $1.36 per share, representing the fair market value per share of the Issuer's common stock on the date of grant; provided that in the event the option is exercised prior to May 5, 2024, or the Reporting Person's employment terminates prior to May 5, 2024 other than due to death, disability or circumstances giving rise to severance under the Reporting Person's employment agreement, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F10 · price: On May 5, 2023, the Issuer canceled an option granted on June 21, 2021. In exchange for the canceled option, the reporting person received 20,000 options to purchase common stock having a lower exercise price with the same vesting terms.

F9 · derivative.exercise_date: 25% of the total number of shares subject to the option vested on June 21, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001728117-23-000057 · wf-form4_168366370450924.xml · derivative · entry 10

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2031-02-25

F13 · derivative.exercise_price: The exercise price of the option is $1.36 per share, representing the fair market value per share of the Issuer's common stock on the date of grant; provided that in the event the option is exercised prior to May 5, 2024, or the Reporting Person's employment terminates prior to May 5, 2024 other than due to death, disability or circumstances giving rise to severance under the Reporting Person's employment agreement, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F8 · price: On May 5, 2023, the Issuer canceled an option granted on February 25, 2021. In exchange for the canceled option, the reporting person received 40,000 options to purchase common stock having a lower exercise price with the same vesting terms.

F7 · derivative.exercise_date: 25% of the total number of shares subject to the option vested on February 25, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001728117-23-000057 · wf-form4_168366370450924.xml · derivative · entry 9

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,784

Underlying: Common Stock · 22,784 shares

Expires 2030-02-14

F13 · derivative.exercise_price: The exercise price of the option is $1.36 per share, representing the fair market value per share of the Issuer's common stock on the date of grant; provided that in the event the option is exercised prior to May 5, 2024, or the Reporting Person's employment terminates prior to May 5, 2024 other than due to death, disability or circumstances giving rise to severance under the Reporting Person's employment agreement, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F6 · price: On May 5, 2023, the Issuer canceled an option granted on February 14, 2020. In exchange for the canceled option, the reporting person received 22,784 options to purchase common stock having a lower exercise price with the same vesting terms.

F5 · derivative.exercise_date: 25% of the total number of shares subject to the option vested on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001728117-23-000057 · wf-form4_168366370450924.xml · derivative · entry 8

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,167

Underlying: Common Stock · 9,167 shares

Expires 2029-12-23

F13 · derivative.exercise_price: The exercise price of the option is $1.36 per share, representing the fair market value per share of the Issuer's common stock on the date of grant; provided that in the event the option is exercised prior to May 5, 2024, or the Reporting Person's employment terminates prior to May 5, 2024 other than due to death, disability or circumstances giving rise to severance under the Reporting Person's employment agreement, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F4 · price: On May 5, 2023, the Issuer canceled an option granted on December 23, 2019. In exchange for the canceled option, the reporting person received 9,167 options to purchase common stock having a lower exercise price with the same vesting terms.

F3 · derivative.exercise_date: 25% of the total number of shares subject to the option vested on December 23, 2020 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001728117-23-000057 · wf-form4_168366370450924.xml · derivative · entry 7

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2029-03-25

F13 · derivative.exercise_price: The exercise price of the option is $1.36 per share, representing the fair market value per share of the Issuer's common stock on the date of grant; provided that in the event the option is exercised prior to May 5, 2024, or the Reporting Person's employment terminates prior to May 5, 2024 other than due to death, disability or circumstances giving rise to severance under the Reporting Person's employment agreement, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.

F2 · price: On May 5, 2023, the Issuer canceled an option granted on March 25, 2019. In exchange for the canceled option, the reporting person received 30,000 options to purchase common stock having a lower exercise price with the same vesting terms.

F1 · derivative.exercise_date: The shares subject to the option are fully vested.

SEC source: 0001728117-23-000057 · wf-form4_168366370450924.xml · derivative · entry 6

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 190,000 shares

Expires 2032-01-05

F12 · price: On May 5, 2023, the Issuer canceled an option granted on January 6, 2022. In exchange for the canceled option, the reporting person received 126,667 options to purchase common stock having a lower exercise price with the same vesting terms.

F11 · derivative.exercise_date: One-third of the total number of shares subject to the option vested on January 6, 2023 and 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001728117-23-000057 · wf-form4_168366370450924.xml · derivative · entry 5

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2031-06-21

F10 · price: On May 5, 2023, the Issuer canceled an option granted on June 21, 2021. In exchange for the canceled option, the reporting person received 20,000 options to purchase common stock having a lower exercise price with the same vesting terms.

F9 · derivative.exercise_date: 25% of the total number of shares subject to the option vested on June 21, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001728117-23-000057 · wf-form4_168366370450924.xml · derivative · entry 4

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2031-02-25

F8 · price: On May 5, 2023, the Issuer canceled an option granted on February 25, 2021. In exchange for the canceled option, the reporting person received 40,000 options to purchase common stock having a lower exercise price with the same vesting terms.

F7 · derivative.exercise_date: 25% of the total number of shares subject to the option vested on February 25, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001728117-23-000057 · wf-form4_168366370450924.xml · derivative · entry 3

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 34,175 shares

Expires 2030-02-14

F6 · price: On May 5, 2023, the Issuer canceled an option granted on February 14, 2020. In exchange for the canceled option, the reporting person received 22,784 options to purchase common stock having a lower exercise price with the same vesting terms.

F5 · derivative.exercise_date: 25% of the total number of shares subject to the option vested on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001728117-23-000057 · wf-form4_168366370450924.xml · derivative · entry 2

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,750 shares

Expires 2029-12-23

F4 · price: On May 5, 2023, the Issuer canceled an option granted on December 23, 2019. In exchange for the canceled option, the reporting person received 9,167 options to purchase common stock having a lower exercise price with the same vesting terms.

F3 · derivative.exercise_date: 25% of the total number of shares subject to the option vested on December 23, 2020 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001728117-23-000057 · wf-form4_168366370450924.xml · derivative · entry 1

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 45,000 shares

Expires 2029-03-25

F2 · price: On May 5, 2023, the Issuer canceled an option granted on March 25, 2019. In exchange for the canceled option, the reporting person received 30,000 options to purchase common stock having a lower exercise price with the same vesting terms.

F1 · derivative.exercise_date: The shares subject to the option are fully vested.

SEC source: 0001728117-23-000024 · wf-form4_167951999562246.xml · derivative · entry 1

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,500

Underlying: Common Stock · 157,500 shares

Expires 2033-03-19

F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on March 20, 2024 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001728117-23-000014 · wf-form4_167931846505758.xml · nonDerivative · entry 1

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 199,388

F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: This transaction was executed in multiple trades at prices ranging from $1.08 to $1.10 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

SEC source: 0001728117-22-000110 · wf-form4_167062432335745.xml · derivative · entry 1

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,500

Underlying: Common Stock · 157,500 shares

Expires 2032-12-06

F1 · derivative.exercise_date: One-third of the total number of shares subject to the option will vest on December 7, 2023 and 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

SEC source: 0001728117-22-000088 · wf-form4_166673132619628.xml · nonDerivative · entry 1

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 205,430

F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: This transaction was executed in multiple trades at prices ranging from $11.881 to $12.078 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold.Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

SEC source: 0001728117-22-000051 · wf-form4_165602440770532.xml · nonDerivative · entry 1

Aranda Richard · CIK 0001867872 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 209,897

F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: This transaction was executed in multiple trades at prices ranging from $6.88 to 7.13 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.